Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial

By sjmartinez • December 16, 2022

Podolanczuk AJ, Kim JS, Cooper CB, Lasky JA, Murray S, Oldham JM, Raghu G, Flaherty KR, Spino C, Noth I, Martinez FJ; PRECISIONS Study Team. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulm Med. 2022 Dec 13;22(1):475. doi: 10.1186/s12890-022-02281-8. PMID: 36514019; PMCID: PMC9746571.

Tags: Clinical Trial, IPF, N-acetylcysteine, protocol, Publications, Pulmonary, Critical Care & Sleep Medicine

Authors’ Reply on Immune-Mediated Liver Injury in HCC

Ennin E, Mallepally N, Dodge JL, Dara L. Authors' Reply on Immune-Mediated Liver Injury in HCC. Liver Int. 2025 Nov;45(11):e70415. doi: 10.1111/liv.70415. PMID: 41122960.

Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist

Prommer EE. Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. J Opioid Manag. 2025 Sep-Oct;21(5):377-387.[...]

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]